What is retatrutide? Receptors, structure and research

What is retatrutide, and what does triple agonist mean?

Retatrutide is the research name for LY3437943, a single peptide described in human study reports as an agonist at glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. ^{[1, 2]}

A peptide is a molecule built from linked amino-acid units. A receptor is a biological molecule that recognizes a signal and participates in a response. An agonist activates a receptor; receptor pharmacology examines that interaction and the resulting activity.

In this context, “triple agonist” describes the target profile of a single peptide, not a mixture of separate compounds. ^[2] In discovery receptor assays, LY3437943 showed activity at these targets, although the reported relative activity was not identical across them. ^[3]

Read the molecular label and the experimental model together. The target profile identifies the receptors under investigation, while the model identifies where an observation was made.

What do the receptor assays actually show?

In laboratory receptor assays, LY3437943 showed balanced glucagon and GLP-1 receptor activity but greater GIP receptor activity. ^[3]

Laboratory experiments conducted outside a living organism are described as in vitro. Here, receptor activity means the response measured in a receptor assay, rather than a result from a human study.

Coskun et al. use “balanced” as a comparative description in the cited discovery abstract; that abstract does not provide numerical receptor-activity ratios or complete assay conditions. ^[3] It therefore supports a qualitative comparison, not an exact ratio between the receptor activities. ^[3]

The discovery publication also includes mouse experiments and a human phase 1 study, making it a mixed-model report rather than a receptor-assay-only publication. ^[3] Those experimental settings should remain separate when interpreting its findings.

The cited human phase 2 abstracts describe randomized comparisons, but they do not separately quantify the contribution of each receptor target. ^{[1, 2]} Receptor activation in an assay and receptor-specific contributions in human research are different questions.

Which structural details are supported?

The cited primary abstracts identify retatrutide as a single peptide but do not provide its complete amino-acid sequence. ^{[2, 3]}

An amino-acid sequence specifies the arrangement of amino-acid units within a peptide. A molecular formula states its elemental composition. These are different kinds of structural information and should not be considered interchangeable.

Neither the cited discovery abstract nor the human phase 2 abstract provides a residue-by-residue modification map or a receptor-bound structural model. ^{[2, 3]} The structural description supported by those abstracts is therefore narrower than a complete molecular specification: they establish peptide classification and reported receptor targets. ^{[2, 3]}

For catalog identity fields, including molecular formula, molecular weight, and catalog code, consult the Retatrutide catalog record. For documentation associated with a particular lot, consult the COA library. COA means certificate of analysis.

The guide How to read a Certificate of Analysis provides a companion reading path. Keep publication-level findings and lot-specific documentation separate when reviewing these materials.

Where does it fit in the incretin research timeline?

The cited publication record includes a discovery report in 2022, randomized phase 2 reports in 2023, and a phase 3 program-design report in 2026. ^{[3, 1, 2, 5]}

Incretins are gut-derived, nutrient-stimulated hormones. For this timeline, the useful comparison is how receptor targets and study designs developed, rather than a ranking of compounds.

In a 2024 review, Drucker describes research extending from GLP-1 receptor agonists to compounds with multiple receptor targets, identifying tirzepatide as a GIP/GLP-1 receptor coagonist. ^[6] A coagonist activates more than one receptor target. The same review discusses retatrutide among compounds enabling glucagon and GLP-1 receptor activation; the discovery receptor assays additionally establish its GIP receptor activity. ^{[6, 3]}

The human study reports add a different level of evidence. Jastreboff et al. describe a randomized, double-blind, placebo-controlled phase 2 study involving 338 adults and lasting 48 weeks. ^[1] Rosenstock et al. describe a randomized, double-blind, parallel-group phase 2 study with placebo and dulaglutide comparators, with assessments at 24 weeks and 36 weeks. ^[2]

These publications document human research designs; they do not replace the receptor assays as the source for the reported relative receptor-activity profile. ^{[1, 2, 3]}

What does the registered study program look like?

The cited registry records include a completed phase 3 study and phase 1 studies with different designs and statuses. ^{[4, 7, 8]}

A trial registry records study characteristics and administrative status. Randomization assigns study groups by chance. Double-blind describes masking of group assignments, while a comparator provides a reference group for a study comparison.

The following entries illustrate the cited registered research record; they are not an exhaustive inventory.

Pharmacokinetics describes how a compound's measured concentration changes over time. Open-label means group assignments are not masked.

Each of these registry records lists Eli Lilly and Company as an industry sponsor. ^{[4, 7, 8]} For the registered primary endpoint and its timing, see the individual registry record rather than assigning a single duration to the program.

Separately, the 2026 human-study design paper by Giblin et al. describes four Phase 3 multicenter, randomized, double-blind studies comparing retatrutide with placebo. ^[5] It describes a basket design with nested studies, independent analyses, and planned statistical error control. ^[5] A basket design groups related research questions within a shared study framework.

A completed registry status is not a results statement. Read status fields and published findings as separate evidence types.

What is established, and what remains unresolved?

The cited sources directly support peptide identity, laboratory receptor activity, and documented human study designs, but not a complete structural or receptor-specific mechanistic account. ^{[1, 2, 3]}

The main boundaries are specific:

• Relative receptor activity: the discovery receptor assays support a qualitative comparison, but the cited abstract does not provide exact numerical activity ratios. ^[3]
• Structural detail: the cited discovery and human phase 2 abstracts do not establish a complete sequence or detailed modification map. ^{[2, 3]}
• Human mechanism: the cited phase 2 abstracts do not isolate each receptor's contribution. ^{[1, 2]}
• Phase 3 findings: the cited NCT05931367 excerpt and TRIUMPH design abstract document status and design, not phase 3 results. ^{[4, 5]}

The human phase 2 reports summarized here also do not describe a retatrutide-versus-tirzepatide comparison. ^{[1, 2]} Their comparator designs should therefore not be read as evidence for that particular comparison.

The clearest reading separates molecular classification, observations within each experimental model, registered study facts, and questions that the cited material does not answer.